IRIDEX Corporation Reports 7.8% Revenue Growth in Q3 2025

IRIDEX Corporation reported its financial results for the third quarter of fiscal year 2025, revealing total revenues of $12.5 million, a 7.8% increase from $11.6 million in the same period last year. For the nine months ending September 27, 2025, revenues reached $38.0 million, up 5.5% from $36.0 million in the prior year. The company experienced a gross profit of $4.0 million for the quarter, down from $4.3 million a year earlier, resulting in a gross margin of 32.1%, compared to 37.3% in the previous year. The decline in gross margin was attributed to a $0.8 million loss on inventory write-downs, which was partially offset by a favorable shift in geographic and product mix.

In terms of operational changes, IRIDEX has implemented cost-saving measures that led to a significant reduction in research and development expenses, which fell by 25.2% to $1.0 million for the quarter. Sales and marketing expenses remained stable, while general and administrative costs decreased by 20.2% to $1.8 million, primarily due to lower consulting expenses. The company reported a net loss of $1.6 million for the quarter, compared to a loss of $1.9 million in the same period last year, reflecting a continued effort to manage expenses amid challenging macroeconomic conditions.

The company’s strategic developments included the issuance of 600,000 shares of Series B convertible preferred stock and a convertible promissory note totaling $4 million, which contributed to a net cash inflow of $6.0 million from financing activities. As of September 27, 2025, IRIDEX had cash and cash equivalents of $5.6 million, an increase from $2.4 million at the end of the previous fiscal year. The company’s working capital also improved to $11.7 million, up from $7.0 million.

Geographically, the United States accounted for 44.8% of total revenues in the third quarter, while Europe, the Middle East, and Africa contributed 32.3%. The company continues to rely on its partnership with Topcon Corporation, which accounted for approximately 31% of total revenues during the quarter. The company’s product lines, including the Cyclo G6 and retina systems, saw increased sales, particularly in probe sales for glaucoma treatments.

Looking ahead, IRIDEX remains cautious about the impact of macroeconomic conditions on capital equipment purchasing demand. The company anticipates that ongoing geopolitical uncertainties and inflation concerns may continue to affect customer purchasing decisions. Despite these challenges, IRIDEX is focused on maintaining its market position and expanding its product offerings, while managing costs effectively to improve profitability in the future.